Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 20
---
gression
rate. The 89% non-progression rate and 29% median reduction in polyp burden in Cohort 2 is likely to be the preferred dosage regimen for
Phase 3.

| 8 |

Tolimidone Developments

On July 16, 2024, we announced Health Canada had
approved a Phase 2a dose confirmation trial of tolimidone in T1D. The study is an Investigator Initiated Trial to be conducted by the
University of Alberta. The trial will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three
months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The trial may
be expanded in due course.

MTX110 Developments

On October 4, 2024, we announced
an update on progression free and overall survival in our Phase 1 trial of MTX110 in rGBM, also known as the MAGIC-G1 study. At that
time, patients 1 and 2 had deceased, with overall survival since the start of treatment of 12 months and 13 months, respectively. Patients
3 and 4 remained in post-study follow-up. Patient 3 had progression free survival of six months and overall survival of 13 months since
start of treatment. Patient 4 has not yet had confirmed progression and therefore had progression free and overall survival of 12 months
since start of treatment.

The Phase 1 study is an open-label,
dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced
delivery, or CED, via implanted refillable pump and catheter.

| 9 |

Our Corporate Information

Our
principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our
principal executive office is +44 29 20480 180. Our corporate website is located at www.biodexahpharma.com. Information contained on our
website is not part of, or incorporated in, this prospectus. Our authorized representative in the United States is Donald J. Puglisi of
Puglisi and Associates. Our agent for service in the United States is Donald J. Puglisi of Puglisi and Associates, located at 850 Library